Work

Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5 + Ida), and 5 days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian Design

Year: 2017

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2017.09.032

Authors: Kiran Naqvi, Garciela Nogueras Gonzalez, Cora Cheung, Naveen Pemmaraju, Elias Jabbour, Guillermo Garcia-Manero, Courtney DiNardo, Maro Ohanian, Nitin Jain, Koichi Takahashi, Yesid Alvarado, Marina Konopleva, Xuelin Huang, Jorge Cortes, Hagop Kantarjian

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2763383015

FWCI: 0.182

Cites:

Cited by: 1

Related to: 10